Completion of 10 Billion Won Convertible Bond Issuance to Major Shareholder at Premium, but Cumulative Dilution of 169% Raises Concerns for Shareholder Value
Aprogen Biologics completed the issuance of the 19th convertible bond worth 10 billion won on May 29, 2026. The conversion price is 4,433 won, a 38% premium over the market price at the time of decision (3,210 won) but currently (3,115 won) the premium is 42%. The bond includes a ratchet clause allowing downward adjustment to a minimum of 3,103 won if the stock price declines.
The proceeds are intended for acquisition of securities in a third-party entity (investment in Acro New Technology Fund). While the major shareholder's premium participation signals confidence in long-term growth, it may also serve to strengthen control and mitigate dilution risk for themselves.
Upon conversion, this CB will add approximately 2.26 million shares (15.65% dilution relative to current shares). Combined with previously issued CBs, the total potential dilution reaches 169.49%, severely impairing existing shareholders' equity value. The downward adjustment clause further compounds dilution risk if the stock price continues to fall.
[AI Comprehensive Analysis]Although the major shareholder's premium investment provides a partial positive signal, the massive cumulative dilution of 169% and the ratchet clause pose significant long-term risks to shareholder value. Investors should exercise caution until tangible returns from the fund investment materialize.
KOSPI Filing Information
Filing: Result of Issuance of Rights Offering or Equity-Related Bonds (Voluntary Disclosure)